Online inquiry

IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10925MR)

This product GTTS-WQ10925MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ10925MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5034MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ2721MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG103
GTTS-WQ1261MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-414
GTTS-WQ13490MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ312MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 19D12
GTTS-WQ9875MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ6200MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ908MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW